Amsterdam

• A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment i … Recruiting
  2023-508204-38-00 5 2024-07-02 Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
• An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617 … Recruiting
  2022-502956-29-00 5 2024-07-01 Oligometastatic prostate cancer (OMPC)
• HYDROchlorothiazide to PROTECT polycystic kidney disease patients and improve their quality of life (HYDRO-PROTECT) Recruiting
  2022-500210-26-00 5 2024-06-28 Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• INJECTABL-II trial: Dose finding, efficacy and immunological response of a novel immuno-adjuvant (IP-001) following microwave ablation or ir … Recruiting
  2023-504572-25-00 9 2024-06-25 Colorectal liver metastases
• Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with long-acting Somatostatin Analogues – ATSA trial Recruiting
  2023-505884-35-00 6 2024-06-17 The study population includes all patients aged over 18 with a neuroen
• NOvel Immunotherapy strategies for advanced Triple negative breast Cancer (TNBC) patients: TONIC-3 trial Recruiting
  2023-507875-23-00 4 2024-06-12 advanced TNBC, eg. irresectable recurrent disease or metastatic disea
• A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients wit … Recruiting
  2022-502404-73-00 4 2024-06-03 Pancreatic ductal adenocarcinoma
• Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID) Recruiting
  2022-502968-20-02 4 2024-05-30 Behcet's disease
• Pro-RAPID Recruiting
  2023-507352-72-00 6 2024-05-24 Crohn's Disease
• PEPPER-trial Recruiting
  2023-507763-18-01 6 2024-05-21 Placenta previa, preterm birth
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• Long-Term Follow-Up of Subjects Treated With NTLA-2002 Recruiting
  2023-507956-56-00 9 2024-05-17 Hereditary Angioedema
• PROMISE Recruiting
  2023-505626-34-01 6 2024-05-16 Chronic kidney disease
• FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – … Recruiting
  2023-508586-33-00 5 2024-05-14 multiple myeloma
• The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients) Recruiting
  2022-500319-38-00 4 2024-05-03 Paroxysmal supraventricular tachycardia (PSVT)
• Metamizole as pain treatment in patients with chronic pancreatitis, a multicenter, randomized, double-blind, placebo-controlled, superiority … Recruiting
  2023-504143-14-00 6 2024-05-02 Chronic pancreatitis
• Basket study for oligo-metastatic breast cancer - ANISE Recruiting
  2023-505039-11-00 4 2024-05-02 breast cancer, HER2-positive, oligometastatic disease
• A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezom … Recruiting
  2023-507632-20-00 5 2024-05-01 Multiple Myeloma
• CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting
  2023-503317-29-00 5 2024-04-12 Metastatic renal cell carcinoma (mRCC)
• HOVON 165 CLL: A prospective randomized phase I/II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in pa … Recruiting
  2022-500305-40-00 9 2024-04-10 Small Lymphocytic Lymphoma
• Phase 1b Study of ION356 to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics in Patients with Pelizaeus-Merzbacher Disease Recruiting
  2022-502432-39-00 1 2024-04-10 Pelizaeus-Merzbacher Disease
• RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previousl … Recruiting
  2022-500031-37-00 5 2024-04-08 ​ stage IA/IIA Hodgkin lymphoma
• STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C … Recruiting
  2023-505871-63-00 5 2024-04-08 ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
• A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch … Recruiting
  2023-504899-25-00 5 2024-04-04 Metastatic castration resistant prostate cancer

Showing 481–504 of 1,112 trials